Want to see ALEC full AI Analyst Report?
ALEC Stock Chart & Stats
$2.57
-$0.09(-4.55%)
At close: 4:00 PM EST
$2.57
-$0.09(-4.55%)
Day’s Range― - ―
52-Week Range$1.09 - $3.40
Previous CloseN/A
Volume194.31K
Average Volume (3M)857.82K
Market Cap
$203.18M
Enterprise Value$130.78M
Total Cash (Recent Filing)$206.51M
Total Debt (Recent Filing)$34.55M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Jul 30, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding111,025,185
10 Day Avg. Volume1,010,411
30 Day Avg. Volume857,816
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.24
Price to Sales (P/S)7.63
P/FCF Ratio-0.87
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue7.10
Enterprise Value/Gross Profit-1.79
Enterprise Value/Ebitda-1.12
Forecast
1Y Price Target
$2.83Price Target Upside10.25% Upside
Rating ConsensusHold
Number of Analyst Covering7
EPS Forecast (FY)-0.94
Revenue Forecast (FY)$6.98M
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginAlector reports a TTM gross margin of roughly 82%, indicating favorable product-level economics for its clinical-stage programs. Durable high gross margins imply that if candidates advance, unit costs are controllable and favorable economics can support scale-up and partner negotiations over months ahead.
Established ATM Financing OptionalityThe $125M ATM program gives Alector flexible, programmatic access to equity capital without a single large dilutive event. Over a 2-6 month horizon this optionality reduces urgency to find immediate financing, allowing measured funding of R&D and operations and better timing of capital raises.
Debt Reduction Improved FlexibilityRepaying and terminating the Hercules loan removes a near-term debt obligation and associated covenants/charges. This durable improvement lowers fixed cash outflows, simplifies the balance sheet and modestly expands strategic flexibility when reassessing partnerships and clinical plans over the coming months.
Bears Say
Pipeline Setbacks And Partner LossMultiple clinical failures and GSK’s decision to terminate the collaboration constitute a structural hit to Alector’s development engine. Loss of a major partner removes expected milestone and funding streams, increases the burden to self-fund development or re-license assets, and raises execution risk over quarters.
Sustained Negative Cash Flow / Cash BurnDeeply negative operating and free cash flow (~-$173M TTM) show persistent cash burn that is unlikely to self-correct quickly. This durable cash gap forces reliance on external capital, elevates dilution risk, constrains R&D sequencing, and reduces resilience to further clinical or financing shocks.
Elevated Leverage From Equity ErosionDebt-to-equity increasing to 3.33 reflects significant equity erosion rather than massive new debt, amplifying financial risk. High leverage limits borrowing capacity, raises financing costs, and reduces flexibility to absorb setbacks; this structural fragility persists until equity is meaningfully rebuilt.
Alector News
ALEC FAQ
What was Alector’s price range in the past 12 months?
Alector lowest stock price was $1.09 and its highest was $3.40 in the past 12 months.
What is Alector’s market cap?
Alector’s market cap is $203.18M.
When is Alector’s upcoming earnings report date?
Alector’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Alector’s earnings last quarter?
Alector released its earnings results on May 07, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.078.
Is Alector overvalued?
According to Wall Street analysts Alector’s price is currently Undervalued.
Does Alector pay dividends?
Alector does not currently pay dividends.
What is Alector’s EPS estimate?
Alector’s EPS estimate is -0.22.
How many shares outstanding does Alector have?
Alector has 111,025,185 shares outstanding.
What happened to Alector’s price movement after its last earnings report?
Alector reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went down -13.934%.
Which hedge fund is a major shareholder of Alector?
Currently, no hedge funds are holding shares in ALEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alector Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.83 (10.25% Upside)
$2.83 (10.25% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 94.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $221.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.39%
12-Months-Change
Fundamentals
Return on Equity
-295.17%
Trailing 12-Months
Asset Growth
-41.24%
Trailing 12-Months
Company Description
Alector
Alector, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering new treatments for neurodegenerative disorders. A key program in its pipeline is AL001, a humanized recombinant monoclonal antibody currently undergoing Phase III clinical trials. This investigational therapy targets a range of severe conditions, including frontotemporal dementia, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Additionally, AL101 is progressing through Phase I clinical trials for general neurodegenerative diseases, with a specific focus on Alzheimer's and Parkinson's. Further bolstering its Alzheimer's portfolio, Alector is evaluating AL002 in Phase II studies and AL003 in Phase I studies, both aimed at addressing Alzheimer's disease. In earlier-stage development, the company is also developing AL044, which targets the MS4A4A gene, identified as a risk factor for Alzheimer's disease. Alector has forged key partnerships to advance its mission. It collaborates with Adimab, LLC on antibody research and development. Furthermore, a significant strategic alliance with GlaxoSmithKline plc (GSK) focuses on the joint development and commercialization of monoclonal antibodies, specifically AL001 and AL101, for neurodegenerative conditions. Established in 2013, Alector's headquarters are located in South San Francisco, California.
ALEC Stock 12 Month Forecast
Average Price Target
$2.83
▲(10.25% Upside)
Technical Analysis
Ownership Overview
7.31% Insiders
11.63% Mutual Funds
38.59% Other Institutional Investors
32.66% Public Companies and
Individual Investors